Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04906512
Other study ID # EM-05-014894
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 14, 2021
Est. completion date March 31, 2022

Study information

Verified date September 2023
Source 3M
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, prospective, randomized controlled clinical trial designed to compare the antimicrobial efficacy of Tegaderm CHG I.V. Securement Dressing and transparent dressings for deep vein catheterization in adult ICU patients.


Description:

This clinical trial is designed as a prospective, randomized, open-label, parallel-group controlled trial. Investigational product: 3M™ Tegaderm™ CHG I.V. Securement Dressing Control product: 3MTM TegadermTM Transparent Film Dressing 1626W Considering the easy-to-distinguish appearances of both products used, this trial will adopt an open-label design. The primary endpoint is the rate of CVC tip colonization (positive catheters after culture/total catheters). Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU. 440 subjects who meet the inclusion/exclusion criteria will be enrolled. Subjects will be adult voluntary clinical subjects, of either sex, at least 18 years of age, who are ICU patients undergoing deep venous catheterization (DVC), in which a CVC catheter must be used while other types of catheters such as hemodialysis, PICCO, and floating catheters may be used concurrently.


Recruitment information / eligibility

Status Terminated
Enrollment 123
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subjects may be included that meet the following criteria: 1. Subjects should be at least 18 years old or older at the time of providing consent; 2. Subjects would be available to attend all visits required in the trial, be inpatients in the Department of Critical Care Medicine and have an expected length of stay in the ICU of no less than 3 days; 3. The subject or his/her legally authorized representative should be competent to sign the informed consent form; 4. The patient must have a central venous catheter (CVC) used on him/her, which may or may not be used in combination with other types of DVCs; 5. The patient's catheter insertion site is free of deformities, phlebitis, infiltrations, dermatitis, eczema, rashes, breaks, burns, tattoos or other skin conditions that may affect the integrity of the skin at the insertion site; 6. The patient would comply with the DVC treatment process and the nursing process prescribed in this protocol. Exclusion Criteria: Subjects may not be included that meet any of the following criteria: 1. The subject is unwilling/unable to attend study visits (unlike IC); 2. There is sunburn, skin infection or scar, mole or other blemishes on the subject's catheterization site that would affect the scoring or measurement of the site; 3. The patient is assessed by the investigator as being at high risk of CLABSI, or known to be CLABSI, based on the environment, duration, and site conditions of catheterization; 4. The patient is documented or known to have allergies (sensitivities) to adhesive products, or other products involved in the trial, e.g. transparent dressings, CHG and alcohol; 5. The patient is being or has been subjected to other antibiotic, catheter or skin-related clinical trials; 6. The patient needs topical application of creams containing antimicrobial ingredients or other antimicrobial fluids beneath the Tegaderm CHG dressing or transparent dressing for skin disinfection, in addition to the requirements of this protocol; 7. The patient is assessed by the investigator as being at high risk of blood stream infection, or known to be sepsis, caused by blood stream infection; 8. The patient has dermatitis, burns, lesions, breaks, eczema, tattoos or other conditions at the catheter insertion site that would interfere with observation in the trial; 9. Women who are pregnant or breast feeding; 10. Patients who are not eligible for the study at the discretion of other investigators.

Study Design


Intervention

Device:
3M™ Tegaderm™ CHG I.V. Securement Dressing
Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
3M™ Tegaderm™ Transparent Film Dressing 1626W
Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.

Locations

Country Name City State
China Ruijin Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
3M

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of CVC Tip Colonization (Positive Catheters After Culture/Total Catheters) Rate of CVC tip colonization (positive catheters after culture/total catheters) 3-14 days
See also
  Status Clinical Trial Phase
Terminated NCT04787926 - DuraLock-C Catheter Lock Solution
Active, not recruiting NCT02515201 - Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children Phase 4
Recruiting NCT04140916 - Comparison of Two Peripheral Inserted Intravenous Catheters N/A
Not yet recruiting NCT06019897 - Impact of Tubing Colonization on the Incidence of Central Venous Catheter Infection
Completed NCT02970409 - Heparin Versus Saline in Peripheral Venous Catheter N/A
Completed NCT03101371 - Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion Phase 2
Completed NCT04821193 - Comparison of the Effects of 5%NaHCO3, 2%CHG and 70%Alcohol in the Prevention of Infections Related to Catheter N/A
Completed NCT04155723 - Impact of a Task Delegation to ICU Nurses for Midlines' Placement
Completed NCT02577718 - Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution Phase 1/Phase 2
Completed NCT02279121 - ATAPAC Study (TauroLock Activity in Adult Cancer Patients) N/A
Completed NCT00965198 - Comparison of Infection Rates Among Patients Using Two Catheter Access Devices N/A
Recruiting NCT05741866 - Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs) N/A
Recruiting NCT04825314 - Noble Meta Alloy Coated Catheters in Patients With Long Term Catheterization N/A
Active, not recruiting NCT03945045 - A Study of the IJV or the SCV Approach for Ultrasound-guided Implantation of TIVAD N/A
Active, not recruiting NCT01592032 - Concentration of Antimicrobials in Catheter-lock Solutions Phase 4
Withdrawn NCT02899780 - Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light N/A
Recruiting NCT05995080 - The Effectiveness of Chlorhexidine Gluconate on Prevention of Catheter-Related Bloodstream Infections N/A
Completed NCT04794231 - Comparison of Chlorhexidine Impregnated Dressing and Standard Dressing N/A
Terminated NCT03447639 - Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal Phase 4
Completed NCT03950921 - Pilot Testing a Patient Safety Display in the Hospital Setting N/A